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Introduction
The introduction of drugs designed to inhibit the effects of TNF-α 
significantly modified the prognosis of multiple chronic inflammatory 
disorders, including rheumatoid arthritis (RA), psoriatic arthritis (PA), 
psoriasis and ankylosing spondylitis (AS). In these diseases that require 
long-term treatment with immunosuppressive therapies, there has 
always been concern that such treatments could increase the risk of 
developing cancer. 
Biological agents acting through complex mechanisms of 
immunomodulation and some cytokines inhibited by these treatments 
(such as TNF-α) exert important biological effects, although not fully 
defined, which can counteract the processes of carcinogenesis and 
tumor progression. We cannot define whether multiple and sequential 
anti-TNF-α may increase the risk of lymphoma, also due to the difficulty 
in correctly estimating the risk in patients with RA who already have 
an increased risk of lymphoma compared to the general population. 
However, there are some reported lymphoma cases during or after 
anti-TNF-α treatment in some rheumatic diseases other than RA [1]. 
Golimumab is a human IgG1 kappa monoclonal antibody approved in 
2009 for moderate to severe active RA, active PA and active AS. 
Case Presentation
A 49-year-old woman was admitted to our clinic in 2009 with a 
history of Crohn disease diagnosed in 2006 following a colonoscopy 
and a double surgery for rectovaginal fistula, initially treated with 
sulfasalazine and later with infliximab, then stopped after four 
infusions following the onset of psoriasis. Next, the patient started 
therapy with steroids and azathioprine, which were however stopped 
after a few months due to ineffectiveness. In 2007, the patient suffered 
onset of asimmetrical hands and feet arthritis, with associated diffuse 
weakness. Based on the above clinical picture and radiological data, 
the patient was further diagnosed with PA. A therapy with etanercept 
plus methotrexate was set, however with no benefit. In February 
2009, immunosuppressive therapy was replaced by adalimumab. 
The clinical manifestations remained steady despite the periodic 
association of high-dose steroids therapy which was also due to the 
onset of a subsequent difficulty in walking, aggravated by the presence 
of a neurogenic pain disease defined as “hereditary neuropathy with 
predisposition to paralysis compression” (HNPP). In view of the 
poor control of the arthritis, at the beginning of 2010 the patient was 
admitted to the Rheumatology Unit and at this stage it was decided to 
reset therapy with infliximab, also in agreement with the patient; this 
therapy was stopped after a few months due to adverse events and was 
replaced by etanercept. In April 2011, the frequent exacerbation of the 
articular symptomatology, characterized by the onset of arthritis in the 
ankles and multiple dactylitis, caused the reduction of methotrexate 
therapy, discontinuation of etanercept and setting the of a therapy with 
another anti-TNF-α monoclonal antibody, golimumab, which allowed 
to obtain a gradual improvement in the clinical condition of the patient. 
In March 2012 the patient complained about the onset of a palpable left 
inguinal lymph node, which was under investigation for biopsy with 
histological follicular low-grade non-Hodgkin lymphoma sec. WHO 
2008 with a predominantly diffuse and rich in T lymphocytes pattern 
Mib1-20%. The blood tests showed minimum levels of leukopenia 
with normal lymphocytes, ESR at the upper limits, normal LDH and 
beta2microglobulina and no hypogammaglobulinemia. Following 
the above histological finding, the patient underwent a hematological 
evaluation and was subjected to further tests for serological and 
instrumental staging of lymphoproliferative disease (normal PET and 
abdominal ultrasound). The inguinal ultrasound showed the presence 
of bilateral lymphadenopathy with no pathologic feature. Non-Hodgkin 
follicular lymphomas have a high radio- and chemosensitivity often 
relapsing after first line treatment. On the basis of the latest evidence 
reported in literature, a therapy was set with anti-CD20 associated 
with radiotherapy. Rituximab is a mouse/human chimeric antibody 
targeting the CD20 antigen on the surface of B-cell lymphoma cells, 
often used in the treatment of B neoplasms expressing the antigen, and 
shown to have activity in some autoimmune diseases. In vitro data 
on B lymphoma cell lines, showed potentiation of radiation-induced 
apoptosis by addition of rituximab. Data from literature show that 
combined radio/immunotherapy is feasible and safe and treatment 
outcome is promising [2,3]. 
In consideration of the concomitant autoimmune disease, the 
limited stage (IA) of the hematological disease and comforted by 
the literature [3], the hematologist proposed a weekly application 
of rituximab (375 mg/m² intravenously once a week for 4 weeks) 
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associated with radiation therapy (total dose 30 Gy). The therapy was 
well tolerated: no clinical evidence of residual hematological disease 
was observed neither during nor after treatment. The patient regularly 
reported persistent joint pain which was treated with low-dose steroids 
and analgesic therapy. 
Discussion
Therapy with biotechnological drugs has radically modified the 
course of chronic inflammatory articular diseases, although it is also 
associated with an increased risk of serious adverse events, including 
the onset of malignancies. On the other hand, the same diseases 
represent, themselves, a risk factor for the development of certain 
malignancies, so it is not easy to determine whether the same therapy 
can be considered to be decisive in the development of the latter. Not 
all the patients satisfactorily respond to the administered treatment, 
therefore for many years they require continuous therapeutic changes, 
probably with an increased risk of adverse events. Moreover there 
are no data in literature which demonstrate whether refractoriness to 
multiple anti-TNF-α agents increases the risk of malignancies. 
Many evaluations of the relative risk of cancer associated with 
anti-TNF-α have come to differing conclusions, with some but not 
all meta-analysis of clinical trial data suggesting that these drugs may 
increase the risk of cancer. An overall increase in the incidence of 
cancers related to biologics in large observational studies has not been 
detected, including those carried out on the national Registers (NDB for 
Rheumatic Diseases for the U.S., Swedish Biologics Register for Sweden, 
BSRBR for the United Kingdom, BIOBADASER for Spain, LOHREN 
for Italy and RABBIT for Germany) and the meta-analyses of clinical 
trials [4-13]. Another recent meta-analysis of data presented in studies 
of registry and prospective observational studies confirm that the anti-
TNF-α does not appear to increase the overall risk of developing cancer, 
with an estimated cumulative risk calculated at 0.95 (95% CI 0.85-1.05) 
[14]. Drugs can increase the incidence of malignancies by initiating 
the cancer process, by promoting progression of a precancerous state 
to invasive cancer, or both. Limited data are available on time since 
initiation of therapy and the risk of cancer. An observational study 
of Askling and coll. conducted on a Swedish database has analyzed 
the risk of cancer development in time after initiation of anti-TNF-α 
therapy and the duration of such therapy without encountering an 
increase of the oncological risk linked to these two variables [5]. Several 
epidemiological studies show that patients with RA, if compared with 
the general population, have an increased risk to develop certain type of 
malignancies, especially lymphoma and cancers of the hematopoietic 
system, lung and skin cancer other than melanoma [4,6,15-17]. The 
relationship between RA and lymphoma has been investigated with 
particular attention. A meta-analysis of studies investigating the risk 
of overall and four specific malignancies in patients with rheumatoid 
arthritis compared with the general population showed a doubled risk 
of lymphoma with a standardized incidence ratio (SIR) of 2.08 (CI 95% 
1.80 - 2.39) [18]. The risk was higher for Hodgkin’s lymphoma (SIR 
3.29 [95% CI 2.56 - 4.22]) compared to a non-Hodgkin lymphoma (SIR 
1.95 [95% CI 1.70 - 2.24]). 
It is difficult to define whether anti-TNF-α may increase the risk 
of lymphoma in RA due to the fact that patients with RA already have 
an increased risk of lymphoma compared to the general population. A 
single case reported in the literature shows the development of CD30+ 
T-cell lymphoma in psoriatic patient treated with ciclosporin and anti-
TNF-α (infliximab) [19]. However, the main observational studies have 
not shown an increased incidence of malignant lymphoma probably 
because the main risk factor for lymphoma seems to lie in the severity 
of the disease, as demonstrated in a case-control study conducted on 
the Swedish Inpatient Register during 1964-1995. Such study showed 
a direct correlation between disease activity and the risk of lymphoma, 
with an increase of the latter in the subgroup of patients with the 
highest activity of disease [20]. Therefore, chronic inflammation 
plays a key role in the risk of lymphoma [20-24]. In order to explain 
this effect it was assumed that in RA persistent immune stimulation 
can lead to a clonal selection of B lymphocytes inducing malignant 
transformation of CD5+ cells, reducing the number and functional 
activity of T suppressor lymphocytes (like those directed against the 
oncogenic virus, Epstein-Barr) and reducing natural killer cell activity 
in the synovial fluid, tissue, blood and lymph [18,20,21]. Another study 
of the Swedish group investigated the possibility of a common genetic 
susceptibility for the development of lymphoma and RA, evaluating 
whether the increased risk of lymphoma was detectable even before 
diagnosis of RA [25]. It was observed that the risk increased only in the 
ten years following the diagnosis of RA, confirming the importance of 
the disease as a determining factor for the increased risk of lymphoma 
[26]. 
Data from the available literature show that the rate of serious 
adverse events in patients treated with golimumab is comparable 
to treatment with other anti-TNF-α. Specifically, in a multicenter, 
randomized, double-blind, placebo-controlled trial, 405 patients with 
active PA were randomly assigned to receive blinded subcutaneous 
injections of placebo, golimumab 50 mg or golimumab 100 mg 
at weeks 0, 4, 8, 12, 16, and 20. Findings over a period of 1 year are 
reported. The frequency/types of adverse events were similar to those 
reported at week 24. In particular, two cases of basal cell carcinoma (in 
patients who received golimumab 50 mg only) were reported. At week 
52, one patient who received golimumab 50 mg, died from small cell 
lung cancer. In addition to this case and the two patients with basal 
cell skin carcinomas, two additional patients had malignancies. One 
patient (receiving golimumab 100 mg) had prostate cancer, and the 
other (receiving placebo and then golimumab 50 mg after entering the 
early escape phase) had colon cancer. In this trial no case of lymphoma 
was reported [27]. 
Conclusion
Patients starting anti-TNF-α therapy should be informed that there 
is no conclusive evidence for an increase in the risk of developing solid 
tumours or lymphomas above that which would be expected for an RA 
population, however ongoing vigilance is required. Patients should 
be examined for potential malignancy if clinically suspected and anti-
TNF-α treatment should be stopped if malignancy is confirmed. There 
are no significant differences identified between anti-TNF-α therapies 
on the risk of malignancy. Clinical trials evaluated the safety of single 
treatments with biotechnological drugs for a limited period of time. 
We do not know if the continuous changes in therapy with anti-TNF-α 
in non responder patients can to constitute a comparable safety profile 
with respect to patients treated with a single anti-TNF-α. Moreover, 
there are no clinical trials reported in literature which assess such aspect 
in patients with a history of many years of therapy with one or multiple 
anti-TNF-α. Important information on this topic can be obtained from 
the evaluation of the national registers. In our case report we decided to 
treat the patient disease with anti-TNF-α agents comforting about the 
data of the literature and also because the evidences show that a high 
disease activity may expose the patient to a higher risk of complications. 
However the tight control at each stage of the treatment is required. 
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